Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2008; 54(6): 79-86

Efficacy of immunoadsorbentin experimental allergicencephalomyelitis

N.M. Gurina, K.I. Bardakhivska,T.M. Kuchmerovska.

    R.E.Kavetsky Institute of Experimental Pathology,Oncology & Radiobiology, National Academy of Sciencesof Ukraine, Kyiv;O.V.Palladin Institute of Biochemistry, National Academyof Sciences of Ukraine, Kyiv



Abstract

Hemoperfusion through the granulated hemoadsorbent SCN, fibrous carbonic adsorbent AUVM and immunoadsorbent (SCN with immobilized MBP) was applied for the treatment of ex- perimental allergic encephalomyelitis (EAE) in guinea pigs. EAE was induced by single subcutaneous injection of 100 µg of MBP in complete Freund’s adjuvant. Hemoperfusion was performed on the stage of EAE manifestation or in latent period. It was found that immunoadsorbent has the highest therapeutic effi- cacy and allows to eliminate up to 32% anti-MBP antibodies from the serum of guinea pigs with EAE, has up to 84% and 90% of adsorptive capacity of small and middle weight endog- enous substances, respectively, and reduces the level of me- tabolites with molecular weight less than 30 kDa in blood plasma up to 36% .

Full text: (PDF, in Ukrainian)

References

  1. Бакалинская О.Н., Сухаренко Н.В., Стрелко В.В. идр. Сорбционные свойства углеродных гемосор-бентов с иммобилизованными белками // Укр. хим.журн. – 1989. – 55, №12. – С.1273–1276.
  2. Палладин А.В., Терлецкая Я.Т., Козулина Е.П. Белкиструктурных образований ткани головного мозга //Укр. биохим. журн. – 1970. – 42, №2. – С.144–154.
  3. de Andres C., Anaya F., Gimenez – Roldan S. Plasmaimmunoadsorption treatment of malignant multiplesclerosis with severe and prolonged relapses // Rev.Neurol. – 2000. – 30, №7. – P.601–605.
  4. Belogurov A.A.Jr., Kurkova I.N., Friboulet A. et al.Recognition and degradation of myelin basic proteinpeptides by serum autoantibodies: novel biomarker formultiple sclerosis // J. Immunol. – 2008. – 180, №2. –P.1258–1267.
  5. Berger T., Rubner P., Schautzer F. et al. Antimyelin anti-bodies as a predictor of clinically definite multiple sclero-sis after a first demyelinating event // N. Engl. J. Med. –2003. – 349, №2. – P.139–1145.
  6. Braun N., Bosch Th. Immunoadsorption, current statusand future developments // Exp. Opin. Invest. Drugs. –2000. – 9, №9. – P.2017–2038.
  7. Cavaletti G., Perseghin P., Dassi M. et al. Extracorpo-real photochemotherapy reduces the severety of Lewisrat experimental allergic encephalomyelitis through amodulation of the function of peripheral bloodmononuclear cells // J. Biol. Regul. Homeost. Agents. –2004. – 18, №1. – P.9–17.
  8. Cho Y.K., Baily J.E. Immobilization of enzymes on acti-vated carbon: Selection and preparation of the carbonsupport // Biotechnol. and Bioeng. – 1979. – 21, №3. –P.461–476.
  9. 9. Egg R., Reindl M., Deisenhammer F. et al. Anti-MOGand anti-MBP antibody subclasses in multiple sclerosis// Mult. Scler. – 2001. – 7, №5. – P.285–289.
  10. 10. Irie H., Sanai J., Nagai Y. Enzyme-linked immunosorbentassay (ELISA) for anti-myelin basic protein antibodyand its application to studies of experimental allergicencephalomyelitis // Jap. J. Exp. Med. – 1981. – 51,№4. – P.201–208.
  11. Keegan B.M., Noseworthy J.H. Multiple sclerosis //Annu. Rev. Med. – 2002. – 53. – P.285–302.
  12. Kuhle J., Lindberg R.L., Regeniter A. et al. Antimyelinantibodies in clinically isolated syndromes correlate withinflammation in MRI and CSF // J. Neurol. – 2007. –254, №2. – P.160–168.
  13. Moldenhauer A., Haas J., Wascher C. et al. Immunoadsorp-tion patients with multiple sclerosis: an open-label pilot study// Eur. J. Clin. Invest. – 2005. – 35, №8. – P.523–530.
  14. Nakane S., Matsuo H., Goto H. et al. Cytapheresis witha filter for selective removal of CD4+ T cells in ex-perimental allergic encephalomyelitis // Mult. Scler. –2003. – 9, №6. – P.579–584.
  15. Sedgwick J., Brostoff S., Mason D. Experimental allergicencephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. Severe paralytic diseasecorrelates with the presence of interleukin 2 receptor-positive cells infiltrating the central nervous system // J.Exp. Med. – 1987. – 165, №4. – P.1058–1075.
  16. Storch M.K., Piddlesden S., Haltia M. et al. Multiplesclerosis: in situ evidence for antibody and complement-mediated demyelination // Ann. Neurol. – 1998. – 43. –P.465–471.
  17. Tomassini V., De Giglio L., Reindl M. et al. Anti-myelinantibodies predict the clinical outcome after a first epi-sode suggestive of MS // Mult. Scler. – 2007. – 13,№9. – P.1086–1094.
  18. Warren K.G., Catz I. The effect of intrathecal MBP syn-thetic peptides containing epitope P85 VVHFFK-NIVTP96on free anti-MBP levels in acute relapsing multiple sclero-sis // J. Neurol. Sci. – 1997. – 148, №1. – P.67–78.
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.